Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH

Launched by SUN YAT-SEN UNIVERSITY · Nov 3, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment for Vogt Koyanagi Harada disease (VKH), a condition that can affect the eyes and may cause vision problems. The trial aims to find out how well a combination of corticosteroids (a type of medication that reduces inflammation) and noncorticosteroid therapies works for patients with VKH. Researchers are looking for participants aged between 12 and 70 who meet specific criteria, such as having a confirmed diagnosis of VKH and being able to safely take the medications involved in the study.

If you decide to participate, you'll receive careful monitoring and support throughout the trial. It's important to note that people with certain other eye diseases, serious health conditions, or those who are pregnant or planning to become pregnant are not eligible to join. This study is currently recruiting participants, and your involvement could contribute to understanding better treatments for VKH.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis is based on Revised International Diagnostic Criteria (Read et al. 2001b).
• • Age from 12 to 70 years old.
• • Patients have no contraindication of prednisone and immunosuppressive therapy, as determined by the investigator based on the results of laboratory and physical examinations.
• • Written informed consent is provided.
• Exclusion Criteria:
• • Patients with other ocular diseases or fundus diseases: diabetic retinopathy, neovascular/wet age-related macular degeneration
• • History of renal or hepatic insufficiency, heart failure, systemic inflammatory disease or any other condition that, in the opinion of the investigator, would put the patients at risk by participating in the protocol.
• • History of infectious disease like chronic or active hepatitis B infection, HIV infection, immunodeficiency syndrome, chronic recurring infections, or active tuberculosis.
• • Female patients who were pregnant or considering becoming pregnant during the study.